Document is current
Any future updates will be listed below
-
Authors
Ruanglertboon, Warit https://orcid.org/0000-0003-0540-7427
Sorich, Michael J.
Logan, Jessica M.
Rowland, Andrew
Hopkins, Ashley M.
-
Funding
Funding for this research was provided by:
Cancer Council South Australia (1127220, 1159924)
National Breast Cancer Foundation (PF-17-007)
- License Information
-
More Information
Article History
Received: 8 May 2020
Accepted: 14 May 2020
First Online: 24 May 2020
Compliance with ethical standards
:
: Dr. Sorich and Dr. Rowland report grants from Pfizer, outside the submitted work. No potential conflicts of interest were reported by the other authors.
: The study was a secondary analysis of individual participant data (IPD). IPD was accessed in this study via , according to Pfizer’s policy and process for data sharing. Secondary analysis of anonymized IPD was deemed negligible risk research by the Southern Adelaide Local Health Network, Office for Research and Ethics and was exempted from review. The NCT00699374 trial conducted by Pfizer was performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee at each study site. All patients provided written informed consent (Cheng et al. ).
: All patients provided written informed consent.
: Data and statistical analyses were performed using R version 3.5.
